Back to Authors

Mangold, A R

0000-0001-6873-1705

Mayo Clinic

Department of Dermatology, Mayo Clinic Arizona, Scottsdale, Arizona, USA.

Citations 63

Single-cell analysis of Sézary syndrome reveals novel markers and shifting gene profiles associated with treatment

Blood Advances | April 7, 2022 | Volume: 7 | Issue: 3 | Pages: 321-335

10.1182/bloodadvances.2021005991 | PMID 35390145

AbstractCutaneous T-cell lymphomas (CTCLs) are a spectrum of diseases with varied clinical courses caused by malignant clonal proliferation of skin-tropic T cells. Most patients have an indolent disease course managed with skin-directed therapies. In contrast, others, especially in advanced stages of disease or with specific forms, have aggressive progression and poor median survival. Sézary syndrome (SS), a leukemic variant of CTCL, lacks highly consistent phenotypic and genetic markers that may be leveraged to prevent the delay in diagnosis experienced by most patients with CTCL and could be useful for optimal treatment selection. Using single-cell mRNA and T-cell receptor sequencing of peripheral blood immune cells in SS, we extensively mapped the transcriptomic variations of nearly 50 000 T cells of both malignant and nonmalignant origins. We identified potential diverging SS cell populations, including quiescent and proliferative populations shared across multiple patients. In particular, the expression of AIRE was the most highly upregulated gene in our analysis, and AIRE protein expression could be observed over a variety of CTCLs. Furthermore, within a single patient, we were able to characterize differences in cell populations by comparing malignant T cells over the course of treatment with histone deacetylase inhibition and photopheresis. New cellular clusters after progression of the therapy notably exhibited increased expression of the transcriptional factor FOXP3, a master regulator of regulatory T-cell function, raising the potential implication of an evolving mechanism of immune evasion.
Consolidation of US dermatology practices

International Journal of Dermatology | December 3, 2021 | Volume: 61 | Issue: 12 | Pages: No page available

10.1111/ijd.16017 | PMID 34859886

Rates of Upstaging, Between Diagnosis and Surgery, and Clinical Management of Metastatic Cutaneous Squamous Cell Carcinoma: A Case–Control Study

Dermatologic Surgery | September 1, 2021 | Volume: 48 | Issue: 1 | Pages: 12-16

10.1097/dss.0000000000003224 | PMID 34904573

BACKGROUND Cutaneous squamous cell carcinomas (cSCC) have upstage rates of approximately 10.3% to 11.1%. Data are currently limited on the rate of upstaging for metastatic cSCC. OBJECTIVE The aim of this study was to determine the rates of upstaging, between diagnosis and surgery, and differences in management for metastatic and non-metastatic high-risk cSCC. MATERIALS AND METHODS This was a retrospective, case–control, single institution, multi-center study. Univariate analysis was used. RESULTS Sixty-eight subjects (34 metastatic & 34 non-metastatic) with 69 tumors were included. The overall rate of upstaging was 46.4%. The most common reasons for upstage were undocumented tumor size and under-diagnosis of poor differentiation. There were no differences in rates of upstaging. Preoperative imaging was performed in 43.6% of wide local excisions (WLE) versus 3.3% of Mohs micrographic surgery (MMS; p < .001). The median days from surgery to sentinel lymph node biopsy (SLNB), or nodal dissection was shorter for WLE versus MMS (0 vs 221 days, p < .001). CONCLUSION Improved clinical documentation, including documenting tumor size, and the identification of pathologic risk factors, including poor differentiation and depth of invasion, are needed for proper staging. Preoperative imaging and discussion of SLNB may be beneficial for high-risk T2b and T3 tumors.
Evaluating the potential cost savings from inpatient dermatology consultations

Journal of the European Academy of Dermatology and Venereology | August 10, 2021 | Volume: 35 | Issue: 12 | Pages: No page available

10.1111/jdv.17595 | PMID 34374133

The evolving understanding of risk with calcitonin gene‐related peptide monoclonal antibodies based on real‐world data: A focus on hypertension and Raynaud phenomenon

Headache: The Journal of Head and Face Pain | August 7, 2021 | Volume: 61 | Issue: 8 | Pages: 1274-1276

10.1111/head.14198 | PMID 34364313

A rare case of childhood mucous membrane pemphigoid involving the oral and genital mucosa

Pediatric Dermatology | May 12, 2021 | Volume: 38 | Issue: 4 | Pages: 904-907

10.1111/pde.14627 | PMID 33977558

AbstractMucous membrane pemphigoid (MMP) is a rare chronic immunobullous disease that involves the mucous membranes and may result in significant scarring and complications if diagnosis is delayed. MMP typically occurs in elderly patients, with very few cases reported in children. Here, we present a 12‐year‐old female patient with childhood‐onset oral and genital MMP, clinically suspected to be lichen sclerosus, but eventually diagnosed as MMP after multiple supportive biopsies and confirmatory direct immunofluorescence. Although treatment was challenging, the combined use of systemic corticosteroids, dapsone, and mycophenolate mofetil was ultimately successful in achieving disease control.
Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination

Leukemia & Lymphoma | May 11, 2021 | Volume: 62 | Issue: 10 | Pages: 2554-2555

10.1080/10428194.2021.1924371 | PMID 33974494

Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon

JAMA Network Open | April 20, 2021 | Volume: 4 | Issue: 4 | Pages: e217934

10.1001/jamanetworkopen.2021.7934 | PMID 33871613

The prognostic value of inositol polyphosphate 5‐phosphatase in cutaneous squamous cell carcinoma in the general population

International Journal of Dermatology | April 16, 2021 | Volume: 60 | Issue: 10 | Pages: No page available

10.1111/ijd.15565 | PMID 33860939

Survival and Glycemic Control in Patients With co-existing Squamous Cell Carcinoma and Diabetes Mellitus

Future Science OA | February 10, 2021 | Volume: 7 | Issue: 5 | Pages: No page available

10.2144/fsoa-2020-0150 | PMID 34046188